Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

NCT05821088 is registered in ClinicalTrials.gov with David Bond, MD as lead sponsor.

NCT NCT05821088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05821088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Lead sponsor
David Bond, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 29, 2023
Completion date
December 31, 2026
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent grade 3b follicular lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, recurrent high grade b-cell lymphoma, not otherwise specified, recurrent primary cutaneous diffuse large b-cell lymphoma, leg type, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent t-cell/histiocyte-rich large b-cell lymphoma, recurrent transformed follicular lymphoma to diffuse large b-cell lymphoma, recurrent transformed marginal zone lymphoma to diffuse large b-cell lymphoma, refractory b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory grade 3b follicular lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory high grade b-cell lymphoma, not otherwise specified, refractory primary cutaneous diffuse large b-cell lymphoma, leg type, refractory primary mediastinal (thymic) large b-cell lymphoma, refractory t-cell/histiocyte-rich large b-cell lymphoma, refractory transformed follicular lymphoma to diffuse large b-cell lymphoma, refractory transformed marginal zone lymphoma to diffuse large b-cell lymphoma